Triglyceride compounds, their preparation methods and applications
By modifying the structure of the active ingredients in hemp seed, triglyceride compounds were synthesized, which solved the problem of poor transdermal absorption, achieving highly effective treatment of atopic dermatitis and preventing recurrence. It has excellent transdermal performance and safety, significantly improves skin lesions and downregulates the expression of key proteins.
Patent Information
- Application Number
- CN202611387821.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-08
- Publication Date
- 2026-11-17
AI Technical Summary
In existing technologies, the active ingredient in hemp seed, triglyceride oleate, has poor transdermal absorption and low bioavailability, making it difficult to effectively treat atopic dermatitis and prevent recurrence. There is also a lack of precise intervention methods targeting inflammatory aging and mitochondrial dysfunction.
A triglyceride compound was designed and synthesized. By introducing terminal alkyne bonds through structural modification, the molecular weight and lipophilicity were reduced, giving it excellent transdermal properties. It also targets the specific protein PKM2 to regulate the mitochondrial pathway and is prepared into ointments and other topical dosage forms for the treatment of atopic dermatitis.
It significantly improves transdermal absorption, enhances bioavailability, increases safety, and strengthens efficacy. It can effectively improve skin lesions, reduce scratching, restore epidermal thickness, downregulate BAX/BAK1 expression, and prevent AD recurrence.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention relates to the field of pharmaceutical technology, specifically to triglyceride compounds, their preparation methods, and applications. Background Technology
[0002] Atopic dermatitis (AD), a typical chronic relapsing skin disease, has always been a significant topic in clinical medicine. Currently widely used treatments, such as corticosteroids and biologics, while effectively controlling acute symptoms to some extent, often lead to various adverse reactions with long-term use, such as skin atrophy and increased risk of infection. More challenging is the extremely high relapse rate once medication is discontinued, making the search for a treatment that can safely relieve symptoms while maintaining long-term efficacy an urgent need. However, modern medicine has not fully elucidated the exact pathogenesis of AD, thus limiting treatment strategies. Against this backdrop, the integration of traditional Chinese and Western medicine in prevention and treatment has become a key research focus. How to regulate the Th2 immune bias and inflammation-induced cellular senescence in the skin through traditional Chinese medicine and its active ingredients, thereby achieving long-term disease control and preventing relapse, has become a core scientific challenge in current research.
[0003] Traditional Chinese medicine's "nourishing blood and dispelling wind" method has unique advantages in treating Alzheimer's disease (AD), and hemp seed is a commonly used medicinal material. The main active ingredient in hemp seed is trilinolein. Figure 10 While drug HW001 possesses anti-inflammatory and barrier-repairing effects, its large molecular weight (~879 Da) and extremely high lipophilicity (LogP=22.93) far exceed the optimal window for transdermal absorption (MW<500, LogP 1-5), making it difficult to penetrate the stratum corneum and resulting in low bioavailability, severely limiting its clinical translation. Currently, the mechanisms of chronic AD (relapse) are not fully understood, and there is a lack of precise interventions targeting the upstream drivers of "inflammatory aging" and "mitochondrial dysfunction." Single-cell sequencing analysis suggests that the mitochondrial outer membrane permeability (MOMP) effector proteins BAX and BAK1 are widely upregulated in keratinocytes of AD lesions, representing core upstream nodes driving keratinocyte differentiation arrest, aging-like phenotypes, and type 2 inflammatory responses. However, existing BCL2 family inhibitors are mostly designed for cancer treatment, making it difficult to simultaneously correct overall MOMP imbalance and lacking a basis for transdermal administration. To date, there are no topical AD drug candidates that focus on restoring mitochondrial homeostasis. Summary of the Invention
[0004] In view of this, the technical problem to be solved by the present invention is to provide triglyceride compounds, their preparation methods and applications. The present invention overcomes the defects of poor transdermal absorption and low bioavailability of hemp seed active ingredients in the prior art. It provides a novel derivative with structural modification, excellent transdermal properties, and the ability to target a specific protein (PKM2) to regulate the mitochondrial pathway, for the efficient treatment of atopic dermatitis and prevention of recurrence.
[0005] The present invention provides triglyceride compounds having the structure shown in formula (I) or a pharmaceutically acceptable salt thereof, a solvent compound of said pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereomer, a tautomer, a racemate, or a combination thereof; Formula (I); Among them, R1, R2, and R3 are each independently -(CH2). n -C≡CH, where n is an integer from 3 to 8.
[0006] In some embodiments, R1, R2, and R3 have the same structure.
[0007] In some embodiments, n is 3, 4, 5, 6, 7, or 8, etc.
[0008] In some embodiments, it has the structure of formula (II): Formula (II).
[0009] This invention provides a method for preparing the aforementioned triglyceride compounds, comprising the following steps: Step 1: Mix ω-alkynyl acid with thionyl chloride and obtain ω-alkynyl chloride through an acyl chloride reaction; Step 2: Mix the ω-acetyl chloride from Step 1 with glycerol, and obtain the triglyceride compound through an esterification reaction; The structural formula of the ω-alkynetic acid is HOOC-(CH2). n -C≡CH, where n is an integer from 3 to 8.
[0010] In some embodiments, the ω-alkynical acid is hept-6-alkynical acid, and the reagent for the esterification reaction further includes triethylamine; The molar ratio of ω-alkynyl acid, thionyl chloride, glycerol and triethylamine is 7.93:11.9:2.50:10.0.
[0011] In the preparation method of the present invention, thionyl chloride is added dropwise to a solution of ω-alkynyl acid (selected from α-5-alkynyl acid, heptyl-6-alkynyl acid, and undecyl-10-alkynyl acid) in anhydrous dichloromethane using N,N-dimethylformamide as a catalyst at 0°C. The reaction is carried out at room temperature for 2 h and then concentrated to obtain the corresponding ω-alkynyl chloride. The dichloromethane solution of the ω-alkynyl chloride is added dropwise to a mixture of glycerol, triethylamine, and dichloromethane and reacted overnight at room temperature. The reaction solution is washed sequentially with 1 mol / L hydrochloric acid, water, and saturated brine, dried with anhydrous sodium sulfate, concentrated, and then subjected to silica gel column chromatography with ethyl acetate / petroleum ether at a volume ratio of 1:30 to 1:10 to obtain the triglyceride compounds.
[0012] This invention provides the use of the triglyceride compounds described herein or the triglyceride compounds prepared by the method described herein in the preparation of medicaments for the prevention and / or treatment of inflammatory skin diseases.
[0013] In some embodiments, the inflammatory skin disease includes at least one of contact dermatitis, atopic dermatitis, eczema, actinic keratosis, keratinization disorder, bullous epidermolysis, pemphigus, exfoliative dermatitis, seborrheic dermatitis, erythema, damage caused by the sun or other light sources, discoid lupus erythematosus, dermatomyositis, and psoriasis.
[0014] In some specific embodiments, the inflammatory skin disease is atopic dermatitis.
[0015] This invention provides the use of the triglyceride compounds described above or the triglyceride compounds prepared by the method described above in the preparation of drugs that inhibit inflammatory aging of skin cells and / or regulate mitochondrial MOMP function.
[0016] This invention provides the application of the triglyceride compounds described herein or the triglyceride compounds prepared by the method described herein in the preparation of drugs targeting PKM2 protein.
[0017] In some embodiments, the pharmaceutical dosage form is any one of ointment, cream, gel, topical solution, paste, plaster, rubber plaster, plaster, tincture, lotion, coating, powder, and lyophilized powder.
[0018] In some embodiments, the triglyceride compounds function by binding to a surface pocket near arginine at position 399 of PKM2 (Arg-399; corresponding to codon 339 in the coding sequence).
[0019] In some embodiments, the mass concentration of the triglyceride compound in the drug is 1%-20%, preferably 5%-15%; it is suitable for topical application to the skin lesions of atopic dermatitis in adults and children.
[0020] In some embodiments, the drug is used to prevent recurrence of atopic dermatitis after clinical remission, and is administered as a local maintenance treatment to the previously affected skin lesion site.
[0021] The present invention provides a medicine comprising the triglyceride compound described herein or a triglyceride compound prepared by the method described herein, and pharmaceutically acceptable excipients.
[0022] Compared with the prior art, the present invention has the following beneficial effects: 1. Significantly enhanced transdermal absorption: The triglyceride compounds provided by this invention have anti-inflammatory and barrier-repairing functions and excellent transdermal performance. Under the premise of continuous monitoring of transepithelial electrical resistance (TEER) to confirm the integrity of the barrier, the in vitro HaCaT cell layered epidermal model showed that the epidermal transport rate of HW161 at 240 minutes was about 9.3%, while the parent compound was almost undetectable on the basal side (transport rate < 0.5%).
[0023] 2. Enhanced safety: The upper limit of the safe concentration of HW161 in cells (2 mM) is approximately 4 times that of the parent compound (500 μM).
[0024] 3. Stronger efficacy: In the MC903-induced AD-like relapse model in BALB / c mice, continuous local administration of HW161 (especially at a 15% concentration) for 56 days showed a dose-dependent effect in improving skin lesions, reducing scratching, restoring epidermal thickness, and downregulating the expression of BAX and p21 in the skin lesions, and was significantly superior to the parent compound at the same concentration.
[0025] 4. Novel Mechanism: This study is the first to discover and verify that this derivative, with moderate affinity (equilibrium dissociation constant K_D = 1.903 µM measured by SPR), targets PKM2 (pyruvate kinase M2), regulates the mitochondrial MOMP (mitochondrial outer membrane permeability) process, downregulates BAX / BAK1 expression, and reverses the inflammatory senescent phenotype of keratinocytes and dermal fibroblasts, thereby preventing AD recurrence. Attached Figure Description
[0026] Figure 1Single-cell RNA sequencing analysis of skin tissues from patients with atopic dermatitis and healthy controls was performed. Figure A shows the nFeature_RNA, nCount_RNA, and percent.mt violin plots of six samples after quality control. Figure B shows the results of hypervariable gene screening: the top 2,000 hypervariable genes (marked in red), with the ten genes with the highest degree of variation individually labeled. Figure C shows the PCA plot of integrated cells after batch correction, colored by group (light blue for the atopic dermatitis group and brown for the healthy control group). Figure D shows the standard deviation of each principal component in an elbow plot; subsequent analyses used the first 20 principal components. Figure E shows the 19 unsupervised clusters identified in all cells in a UMAP plot. Figure F shows the 19 cell types based on annotations of typical marker genes in a UMAP plot. Figure 2 The study demonstrates that the MOMP mechanism is upregulated in atopic dermatitis lesions and acts as an upstream regulator of keratinocyte differentiation. Figure A shows a UMAP visualization of 21,539 cells from atopic dermatitis (AD) and healthy control (HC) skin, colored according to 19 annotated cell types. Figure B shows the cellular composition of seven keratinocyte (KC) and fibroblast (FB) subsets in AD and HC, with a stacked bar chart of subset percentages on the left. The middle and right sides show UMAP maps of cell subsets in HC and AD, respectively. Figure C shows the expression of BAX in each KC / FB subset. The left image shows HC, and the right image shows the UMAP feature map of AD; the split violin diagram compares AD (dark purple) and HC (light purple); image D shows the landmark pathway scores at the group level (top) and by subgroup stratification (bottom); image E shows the top 20 genes most affected by computer simulation knockout of BAX (left) and BAK1 (right) using scTenifoldKnk, sorted by log2 fold change; image F is a Venn diagram of the list of the top 20 knockout genes of BAX and BAK1; the bottom shows 9 common core genes; image G shows the functional classification of BAK1-specific (n = 11), common (n = 9), and BAX-specific (n = 11) perturbation genes; image H is a heatmap of network shifts (log2 fold change) of the 9 common core genes; AD, atopic dermatitis; HC, healthy control; KC, keratinocytes; FB, fibroblasts; KO, knockout; MOMP, mitochondrial outer membrane permeability; Figure 3The images show the expression of BAK1 and BCL2 in keratinocyte and fibroblast subsets of skin from atopic dermatitis and healthy controls. Figure A shows BAK1 expression, with a UMAP feature map above illustrating the expression intensity of BAK1 in healthy controls (left) and atopic dermatitis (right), and a violin plot of BAK1 expression levels in seven keratinocyte and fibroblast subsets below. Figure B shows BCL2 expression, with a UMAP feature map above illustrating the expression intensity of BCL2 in healthy controls (left) and atopic dermatitis (right), and a violin plot of BCL2 expression levels in the same subset below. Both transcripts showed low overall abundance and sparse detection across cells, consistent with the known loss of low-expression genes in droplet-based single-cell RNA sequencing. Nevertheless, a moderate upregulation of expression was observed in the atopic dermatitis group within specific subsets, which is consistent with... Figure 2 This is consistent with the widespread activation trend of the mitochondrial outer membrane permeability mechanism shown; Figure 4 This paper presents a design strategy for alkynyl fatty acid glyceride derivatives based on lipophilicity optimization. Figure A shows the chemical structure of the parent compound, triolein, and its transdermal delivery bottlenecks: high molecular weight (~879 Da) and excessively high calculated LogP value (cLogP = 22.93). Figure B shows the core design strategy and structure of derivatives HW162, HW161, and HW160. Figure C shows the cLogP values and water solubility trends of derivatives HW162, HW161, and HW160. Figure 5 This study presents the in vivo efficacy screening and transdermal transport evaluation of lipophilic optimized alkyne fatty acid glyceride derivatives. Figure A shows the in vivo efficacy evaluation flowchart of an MC903-induced atopic dermatitis-like model, with H&E-stained ear tissue sections (scale bar: 100 μm). Figure B shows the transdermal transport evaluation based on a HaCaT cell-layered epidermal model, with the left figure showing the experimental model and dosing regimen, and the right figure showing the quantitative results of epidermal transport rate. Representative HPLC chromatograms of the basal side samples are attached below, showing the HW161 content at 0 minutes and 240 minutes, respectively; ns: no statistical difference. P < 0.001; Figure 6 The structure (A) and HNMR spectrum (B) of the triglyceride derivative HW160 are shown. Figure 7 The structure (A) and HNMR spectrum (B) of the triglyceride derivative HW161 are shown. Figure 8 The structure (A) and HNMR spectrum (B) of the triglyceride derivative HW162 are shown. Figure 9A flowchart illustrating the establishment of an AD mouse model; Figure 10 This study compares the in vivo efficacy of triglyceride trioleate (HW001) and its derivative HW161. Figure A shows the AD-like skin lesions induced by daily application of MC903 to the right ear of BALB / c mice. From Day 0, mice were topically treated daily with Vehicle, 15% HW001, or different concentrations of HW161 (5%, 10%, 15%) for 56 consecutive days. Figure B shows representative photographs of the ears of mice in each group on Day 56. HW161 improved the skin lesions in a dose-dependent manner, with the 15% HW161 group showing the most significant effect and superior to the equal concentration HW001 group. Figure C shows the quantitative results of the number of scratches during the treatment period. HW161 dose-dependently alleviated MC903-induced itching behavior. Figure D shows representative immunohistochemical images (scale bar: 100 μm) of BAX (top) and p21 (bottom) in ear tissue and the quantitative analysis of the positive area. HW161 dose-dependently downregulated the expression of BAX and p21, with the 15% group approaching the normal control level. P < 0.05; P < 0.01; P < 0.001; Figure 11 The results show that HW161 has higher cellular safety and stronger anti-inflammatory and senescence-promoting activity than its parent compound HW001. Figure A shows the cytotoxicity curves of HW001 and HW161 in mouse primary dermal fibroblasts as determined by the CCK-8 assay. The upper limit of safe concentration for HW161 is 2 mM, approximately four times that of HW001 (500 µM). Figure B shows the representative SA-β-gal staining (scale bar: 100 μm) and the quantitative proportion of positive cells in an IL-4 + IL-6 induced inflammatory senescence model of fibroblasts. Figure C shows the expression levels of BAX and BAK1 proteins detected by Western blot and their quantitative grayscale values. HW161 dose-dependently downregulates IL-4 / IL-6 induced BAX and BAK1 expression. P < 0.05; P < 0.01; P < 0.001; Figure 12 A technical roadmap showing the chemical synthesis of HW161 and the combined click chemistry and protein proteometry targeting; Figure 13This paper presents the chemical proteomics identification and binding site verification of HW161 directly targeting PKM2. Figure A shows the CuAAC reaction between HaCaT lysis buffer and the azide-Cy3 probe after incubation with HW161; the upper figure shows Cy3 fluorescence imaging, indicating a dose-dependent enhancement of protein labeling. The lower figure shows the Coomassie Brilliant Blue (CBB) staining control. Figure B shows the Coomassie staining of proteins enriched by streptavidin magnetic beads after HW161 concentration gradient treatment; the HW161 group showed significantly enhanced enrichment compared to the DMSO control. Figure C shows representative total ion chromatograms of the enriched proteins from the HW161 group and the DMSO control group analyzed by LC-MS / MS. Figure D shows the GO of HW161-bound proteins. (BP / MF) and KEGG enrichment analysis bubble charts show significant enrichment in glycolysis, pyruvate metabolism, and TCA cycle pathways. Figure E shows the Venn diagram of proteins detected in both the HW161 and DMSO groups. The HW161 group specifically enriched 196 proteins, of which 71 had significantly higher signal intensities than the control. Right: Top candidate target protein list, PKM ranked first among glycolysis-related proteins with a peptide coverage of 48.1% (marked in red). Figure F shows representative LC-MS / MS secondary mass spectra of PKM characteristic peptides, with good b / y ion matching. Figure G shows CETSA verification; after pre-incubation with HW161 or DMSO, HaCaT lysis buffer was analyzed at 52, 57, 62, 67, and 72 μL. Heating at °C and Western blot analysis of soluble PKM showed that the HW161 group retained more PKM than the DMSO group at all temperature points. β-Actin was used as an internal control. Figure H is a DARTS validation. At a fixed pronase concentration (1:300), the PKM resistance to enzymatic degradation increased with increasing HW161 concentration. β-Actin was used as an internal control. Figure I is the SPR binding curve of HW161 and recombinant PKM2, K~D~ = 1.903 µM. Figure J shows molecular docking, indicating that HW161 is anchored in the PKM2 surface pocket and forms a key hydrogen bond with Arg-399 residues. Detailed Implementation
[0027] This invention provides triglyceride compounds, their preparation methods, and applications. Those skilled in the art can refer to the content of this document and appropriately modify the process parameters to achieve the desired results. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included in this invention. The methods and applications of this invention have been described through preferred embodiments. Those skilled in the art can clearly modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit, and scope of this invention to realize and apply the technology of this invention.
[0028] This invention provides a triglyceride compound (i.e., a triolein derivative) as shown in formula (I), or its solvate or stereoisomer: Equation (I); Among them, R1, R2, and R3 are each independently -(CH2). n -C≡CH, where n is an integer from 3 to 8; In a preferred embodiment, R1=R2=R3 (symmetric triester).
[0029] Representative compounds (R1=R2=R3) include: n=3 corresponds to hex-5-acetylacetyl (C6 acyl), i.e., HW160; n=4 corresponds to heptyl-6-acetyl (C7 acyl), i.e., HW161; n=8 corresponds to undecyl-10-acetylacetyl (C11 acyl), i.e., HW162.
[0030] It should be noted that in formula (Ⅰ), the substituent is connected to the glycerol skeleton via an —O—C(=O)—ester bond, and the carbon number (C6 / C7 / C11) of the above acetyl group has been included in the carbonyl carbon based on fatty acid calculations; therefore, the substituent -(CH2) n -C≡CH has one less carbon atom than the corresponding acyl group (for example, when n=4, the substituent has 6 carbons, and the corresponding aliphatic acyl group is a C7 hept-6-ynyl group).
[0031] The calculated lipophilicity parameters (cLogP) of the three compounds are as follows: 9.10 for HW162, 4.09 for HW161, and 2.84 for HW160. They form a gradient series from the highest lipophilicity (HW162) to the lowest (HW160), covering the optimal cLogP window for transdermal drug delivery (where HW161 with n=4 has cLogP≈4 and is located in the middle of this window).
[0032] Among them, HW161 (cLogP≈4) showed the best efficacy in in vivo in a MC903-induced atopic dermatitis-like model and in in vitro transdermal transport experiments based on a HaCaT cell-layered epidermal model, making it the most preferred lead compound of this invention.
[0033] Key areas for improvement: Structural modification: Replace the long-chain linoleic acid (C18:2) in the parent molecule with a short-chain alkyne fatty acid (such as C7 or C11) with a terminal alkyne bond.
[0034] Physicochemical property optimization: The introduction of alkyne bonds as bioisosteres significantly reduced the molecular weight (to below 500 Da) and lipophilicity (the cLogP of HW161 decreased to 4.09), bringing it into the optimal range for transdermal absorption.
[0035] Click chemistry sites: Terminal alkyne bonds not only regulate activity, but also provide convenient chemical modification sites for subsequent drug target identification (click chemistry).
[0036] The test materials used in this invention are all commercially available products. The invention will be further illustrated below with reference to specific embodiments.
[0037] Example 1: Screening and Synthesis of Derivatives
[0038] 1. The MOMP mechanism is upregulated in atopic dermatitis lesions and serves as an upstream driver of keratinocyte differentiation arrest, senescent features, and type 2 inflammatory responses.
[0039] To analyze the cellular profile of chronic atopic dermatitis (AD), we analyzed the GSE153760 single-cell RNA sequencing dataset (containing biopsy samples from 3 chronic AD lesions and 3 healthy controls). After quality control and batch correction ( Figure 1 A total of 21,539 cells were retained, and clustering yielded 19 annotated cell types, including 7 keratinocyte and fibroblast subsets spanning the complete epidermal differentiation continuum and dermal compartments. Figure 2 Component analysis revealed significant remodeling of structural cell compartments in AD lesions: basal keratinocytes increased 6-fold (36%). vs 6%), terminally differentiated granular keratinocytes decreased by half (14%). vs 28%), while fibroblasts decreased sharply (4%). vs (24%), which reproduced the manifestations of differentiation arrest and dermal cell reduction, similar to the phenotype of endogenous skin aging.
[0040] Given the central role of mitochondrial dysfunction in driving aging and chronic inflammation, we examined three key regulators of mitochondrial outer membrane permeability—BAX, BAK1, and BCL2. The major effector protein BAX was extensively upregulated in almost all keratinocyte / fibroblast subsets in AD, particularly in basal, supraspinous, and circulating basal keratinocytes. Figure 2 AB); BAK1 and BCL2 show similar but milder trends ( Figure 3 Consistent with the mechanism of sublethal "minority MOMP" signaling activation and atypical apoptosis, AD cells showed significantly elevated scores in pathways including apoptosis, p53 pathway, hypoxia response, inflammation response, PI3K-AKT-mTOR, DNA repair, G2 / M checkpoint inhibitors, and DNA replication. These characteristics are closely associated with mitochondrial apoptosis signaling and are typical manifestations of aging-related secretory phenotypes. Proliferation-related programs are mainly concentrated in circulating basal keratinocytes, while inflammatory programs are enriched in basal keratinocytes (…). Figure 2 D).
[0041] To investigate whether MOMP is located at an upstream causal regulatory position, we used scTenifoldKnk to perform a virtual knockout analysis of BAX and BAK1 in the AD keratinocyte regulatory network. Figure 2 (EH). Notably, both independent perturbations point to a highly overlapping set of genes: 9 of the 20 genes with the most significant expression changes are shared by both, 7 of which are classic markers of terminal keratinocyte differentiation. Beyond this common core, the two effectors exhibit partial functional differentiation: BAK1 preferentially affects paracrine inflammatory mediators, while BAX primarily affects cell cycle regulators and hypoxia-responsive mitochondrial regulators. These data collectively establish the MOMP mechanism as a core upstream regulatory node in AD lesions, simultaneously regulating terminal keratinocyte differentiation, aging-related inflammatory responses, and proliferation-differentiation balance. The convergent yet differentiated function of BAX and BAK1 suggests that a strategy of inhibiting only BCL2 family members is insufficient to reverse MOMP dysregulation. Instead, an upstream intervention strategy focusing on restoring overall mitochondrial homeostasis should be adopted. This makes MOMP a previously unrecognized but clinically feasible therapeutic target for AD.
[0042] 2. Based on the lipophilicity-optimized triglyceride alkyne derivative, highly efficient transdermal MOMP-regulating lead compounds were screened.
[0043] The research group used modern biological methods and HPLC-NMR nuclear magnetic resonance technology to isolate and screen the active substances in hemp seed. Through multiple column chromatography, 12 derivative components were isolated from the ethanol extract, and the in vitro inhibitory activity of all compounds against IL-4 and TNF-α was evaluated. Among them, trilinolein, the main active ingredient of hemp seed (Cannabis sativa), was able to alleviate type 2 inflammation and skin barrier dysfunction in an atopic dermatitis model by restoring mitochondrial function.
[0044] However, its large molecular weight (approximately 879 Da) and high calculated lipophilicity (cLogP = 22.93) significantly exceed the empirical window for transdermal absorption (molecular weight < 500 Da; LogP 1–5), limiting its further development. Figure 4 A). Using triolein as the lead structure, this embodiment replaces the three linoleic acyl groups with three shorter ω-alkynyl fatty acyl groups to design HW160, HW161, and HW162 ( Figure 4 B). The terminal alkynyl group also provides a reaction site for subsequent CuAAC labeling.
[0045] 3. Synthesis of derivatives
[0046] 3.1 General Synthesis Method
[0047] ω-acetylic acid was dissolved in anhydrous dichloromethane (10 mL), and a catalytic amount of N,N-dimethylformamide was added. 1.5 equivalents of thionyl chloride were then added dropwise at 0 °C. After the addition was complete, the mixture was allowed to rise to room temperature for 2 h. The volatile components were then concentrated to obtain the corresponding ω-acetylic acid chloride.
[0048] The structural formula of ω-alkynyl acid is HOOC-(CH2). n -C≡CH, where n is an integer from 3 to 8.
[0049] The obtained ω-acetyl chloride was dissolved in dichloromethane (5 mL) and added dropwise to a mixture of glycerol, triethylamine, and dichloromethane (10 mL). The mixture was reacted overnight at room temperature. The reaction solution was washed successively with 1 mol / L hydrochloric acid, water, and saturated brine. The organic phase was dried over anhydrous sodium sulfate and then concentrated. The residue was purified by silica gel column chromatography, eluting with a gradient of ethyl acetate / petroleum ether at a volume ratio of 1:30 to 1:10.
[0050] 3.2 Synthesis of HW160
[0051] Hexano-5-acetylic acid (1.00 g, 8.92 mmol) was dissolved in anhydrous dichloromethane (10 mL), and a catalytic amount of N,N-dimethylformamide was added. Thionyl chloride (1.59 g, 13.4 mmol, 1.5 equivalents) was added dropwise at 0 °C, and the reaction was carried out at room temperature for 2 h. After concentration, the resulting acyl chloride was dissolved in dichloromethane (5 mL), and added dropwise to a mixture of glycerol (0.25 g, 2.70 mmol), triethylamine (1.10 g, 10.9 mmol), and dichloromethane (10 mL). The mixture was reacted overnight at room temperature. Purification was performed using a standard post-treatment method to obtain HW160 (0.70 g, 69% yield), a clear yellow oil. ¹H NMR (400 MHz, CDCl3) δ 5.306~5.265 (1H, m), 4.346~4.313 (2H, m), 4.187~4.152 (2H, m), 2.504~2.4 69 (6H, m), 2.294~2.251 (6H, m), 1.989~1.978 (3H, m), 1.887~1.820 (6H, m).
[0052] 3.3 Synthesis of HW161
[0053] Heptan-6-alkynyl acid (1.00 g, 7.93 mmol) was dissolved in anhydrous dichloromethane (10 mL), and a catalytic amount of N,N-dimethylformamide was added. Thionyl chloride (1.41 g, 11.9 mmol, 1.5 equivalents) was added dropwise at 0 °C, and the reaction was carried out at room temperature for 2 h. After concentration, the resulting acyl chloride was dissolved in dichloromethane (5 mL), and added dropwise to a mixture of glycerol (0.23 g, 2.50 mmol), triethylamine (1.00 g, 10.0 mmol), and dichloromethane (10 mL). The mixture was reacted overnight at room temperature. Purification was performed using a standard post-treatment method to obtain HW161 (0.40 g, 38% yield), a clear yellow oil. ¹H NMR (400 MHz, CDCl3) δ 5.327~5.275 (1H, m), 4.363~4.323 (2H, m), 4.199~4.154 (2H, m), 3.411~2.367 (6H, m), 2.264~2.223 (6H, m), 1.996~1.982 (3H, m), 1.811~1.735 (6H, m), 1.662~1.570 (6H, m).
[0054] 3.4 Synthesis of HW162
[0055] Undecyl-10-alkynyl acid (1.00 g, 5.49 mmol) was dissolved in anhydrous dichloromethane (10 mL), and a catalytic amount of N,N-dimethylformamide was added. Thionyl chloride (0.98 g, 8.23 mmol, 1.5 equivalents) was added dropwise at 0 °C, and the reaction was carried out at room temperature for 2 h. After concentration, the resulting acyl chloride was dissolved in dichloromethane (5 mL), and added dropwise to a mixture of glycerol (0.16 g, 1.74 mmol), triethylamine (0.70 g, 7.00 mmol), and dichloromethane (10 mL). The mixture was reacted overnight at room temperature. Purification was performed using a standard post-treatment method to obtain HW162 (0.70 g, 69% yield) as a clear yellow solid. ¹H NMR (400 MHz, CDCl3) δ 5.284~5.243 (1H, m), 4.310~4.278 (2H, m), 4.163~4.127 (2H, m), 2.333~2.297 (6H, m), 2.197~2.164 (6H, m), 1.944~1.933 (3H, m), 1.639~1.581 (6H, m), 1.549~1.491 (6H, m), 1.419~1.362 (6H, m), 1.340~1.270 (18H, m).
[0056] 4. Derivative screening results
[0057] The three derivatives differ only in the chain length of the ω-alkynyl fatty acid: undecyl-10-alkynyl (C11, HW162), hepta-6-alkynyl (C7, HW161), and hexano-5-alkynyl (C6, HW160), thus forming a series of compounds with progressively decreasing lipophilicity (calculated LogP values of 9.10, 4.09, and 2.84, respectively), covering the theoretically optimal range for transdermal drug delivery. Figure 4 B and Figure 4 C).
[0058] As predicted by theoretical physicochemical parameters, the aqueous phase behavior of the three derivatives was significantly improved compared to the parent compound triglyceride, which is essentially insoluble in water, with water solubility increasing in a gradient with decreasing fatty acid chain length. Figure 4 C). To evaluate its in vivo efficacy, we used an MC903-induced aplastic dermatitis mouse model and administered trilinolein, three derivatives, or the clinical positive control dexamethasone (DEX) topically once daily for 14 days, starting from Day 0. Figure 5 A). The results showed that among the three derivatives, HW161 had the most significant improvement in the appearance of skin lesions: on day 14 of treatment, compared with the MC903 group and the maternal trilinolein group, the HW161 group mice showed a significant reduction in ear erythema, scaling, and lichenification, and the skin appearance was close to the normal control level, which was better than the positive drug DEX group ( Figure 5 A). H&E staining further confirmed this result: the HW161 group significantly inhibited MC903-induced epidermal hyperkeratosis, acanthosis, and dermal inflammatory cell infiltration, and its histological structure was closest to that of the normal control. Figure 5 A). In contrast, HW162 (cLogP = 9.10), with the highest lipophilicity, showed limited efficacy, possibly due to its high LogP content causing it to remain in the stratum corneum and hindering its distribution into the active epidermis. HW160 (cLogP = 2.84), with the lowest lipophilicity, also performed worse than HW161, possibly due to its low LogP content making it difficult to penetrate the stratum corneum lipid barrier. Both findings suggest that HW161's cLogP ≈ 4.0 is within the optimal window for transdermal delivery, representing the best balance between stratum corneum penetration and active epidermal distribution.
[0059] Example 2: Transdermal Absorption Experiment
[0060] To directly quantify transdermal delivery efficiency, we established a layered epidermal transport experimental model based on HaCaT cells ( Figure 5B). HaCaT cells were seeded in collagen-coated Transwell chambers and induced to differentiate on day 4 using high-calcium medium, forming a layered epidermal-like structure with barrier function. Transepithelial resistance (TEER), as the gold standard indicator reflecting the integrity of epithelial tight junctions, was used to confirm successful barrier establishment before each experiment and to continuously monitor barrier status during transport experiments. Results showed that the TEER values in both the trilinolein group and the HW161 group showed no significant change from the baseline at 0 min after 240 min of drug administration. Figure 5 (B) This confirmed that the epidermal barrier remained intact throughout the transport experiment, and the observed compound penetration was genuine transepidermal transport under physiological barrier conditions, rather than non-specific leakage caused by barrier damage. Based on this, we added equimolar amounts of trilinolein or HW161 to the top chamber, collected the basal-side culture medium at 240 min, quantified the compound concentration by HPLC, and calculated the epidermal transport rate as the percentage of drug recovered from the basal side relative to the amount administered at the top. The results showed that trilinolein was almost undetectable on the basal side (transport rate <0.5%), while HW161 achieved an epidermal transport rate of approximately 9.3% at 240 min. Figure 5 B). Compared to the parent compound, HW161 exhibits significantly improved epidermal transport efficiency. Combined with its excellent in vivo efficacy in the MC903 model, we identified it as the top priority compound and will conduct subsequent mechanism and target identification studies.
[0061] Example 3: Pharmacodynamic Evaluation of Animal Models
[0062] 1. Experimental Methods
[0063] 1.1 Establishment of AD mouse model (e.g.) Figure 9 (as shown) Centrifuge 5 mg of MC903 (S3739, Selleckchen) dry powder at 13000 rpm for 3 min, then add 242.363 μl of anhydrous ethanol to prepare a 50 mM stock solution, which is then aliquoted and stored at -20℃. Each time, take 1 μl of 50 mM MC903 and add 999 μl of anhydrous ethanol to prepare a 50 μM working concentration. Six-week-old SPF-grade male BALB / c mice were selected and housed under standard conditions for three days under a 12-hour light / dark cycle, at 25℃ and 55% humidity to acclimatize. Then, they were randomly divided into three mice per cage. After numbering, the skin on the midline of the neck and back of the mice was shaved completely with an electric shaver to expose an area of approximately 2 cm x 2 cm. Two hours later, 20 μL of MC903 was pipetted and evenly applied to the ears of the mice. Stimulation was performed at the same time on Mondays, Wednesdays, and Fridays for 14 consecutive days (day 0-day 14). After successful model establishment, drug administration was suspended for 21 days (day 15-day 35) until the skin lesions of mice in each group were completely relieved. Then, drug administration was continued for another 21 days to establish an AD skin lesion recurrence model (day 35-day 56). The experimental groups were given different concentrations of the parent compound and its derivatives, or dexamethasone cream (positive control), throughout the treatment. Mouse body weight, SCORAD score of skin lesions, and frequency of hind paw scratching were recorded before and after drug administration.
[0064] 1.2 Experimental Grouping: Groups: Model group, parent compound group (trilinolein, 15% HW001), low-, medium- and high-dose HW161 groups (5%, 10%, 15%), and dexamethasone cream group.
[0065] 2. Results
[0066] 2.1 HW161 exhibits dose-dependent anti-inflammatory and antioxidant effects in an MC903-induced AD-like mouse model.
[0067] Results: After 56 days of continuous administration, both the Scores of Skin Lesions (SCORAD) and scratching behavior in the HW161 treatment group showed dose-dependent improvement. Skin lesion improvement was observed with 5% HW161, and the appearance of ear lesions in mice in the 10% and 15% HW161 groups was close to that of normal controls. Ear histopathology with H&E staining showed a significant reduction in epidermal thickening and dermal inflammatory cell infiltration, and a simultaneous dose-dependent decrease in the area of positive BAX and p21 immunohistochemical staining. The 15% HW161 group showed better improvement in skin lesion morphology, pruritus behavior, and aging-like molecular markers than the 15% HW001 group, suggesting that HW161 simultaneously blocks the vicious cycle of AD-related "pruritus-scratching-MOMP activation-aging-like behavior," and its overall efficacy is superior to that of the parent compound HW001.
[0068] To systematically evaluate the in vivo therapeutic potential of the lead compound HW161 and further confirm its superior activity compared to the parent compound, we established an MC903-induced recurrent AD-like dermatitis model in BALB / c mice. Starting from day 0, the right ear was treated daily with a vehicle, 15% trilinoleic acid glyceride (HW001), or different concentrations of HW161 (5%, 10%, 15%) for 56 consecutive days. Uninduced mice served as normal controls. Figure 10 A). The results showed that compared with the MC903 model group alone, the 15% HW001 group showed improvement in ear erythema, scaling, and lichenification, validating the basic anti-AD activity of the parent compound; while the efficacy of the HW161 treatment group showed a clear dose-dependent relationship: skin lesion improvement was observed with 5% HW161, and the skin lesion appearance of the 10% and 15% HW161 groups was close to the normal control level, with better treatment effect than the same concentration (15%) of the parent compound HW001. Figure 10 B). Considering that itching is one of the most distressing symptoms in AD patients, we quantitatively recorded the number of scratches in mice during drug administration. The results showed that MC903 induced a significant increase in scratching behavior in mice, and all dose groups of HW161 dose-dependently relieved itching. The 15% HW161 group showed a greater reduction in scratching frequency than the 15% HW001 group, suggesting that HW161 not only improves the morphology of skin lesions but also effectively blocks the vicious cycle of AD-related itching-scratching. Figure 10 C). To verify at the molecular level whether HW161 exerts its therapeutic effect by targeting the MOMP pathway, we used immunohistochemistry to stain and quantify the key MOMP effector protein BAX and the senescence-related cell cycle inhibitor p21 in ear tissue. The results showed that the expression levels of BAX and p21 in the MC903 model group were significantly upregulated compared to the normal control group, indicating activation of mitochondrial outer membrane permeability and enhanced senescence-like phenotypes of keratinocytes, respectively. After HW161 intervention, the proportion and staining intensity of BAX and p21-positive cells decreased in a dose-dependent manner, with the 15% HW161 group approaching normal levels. Figure 10 (D) confirmed that HW161 can effectively reverse MOMP activation and aging-like phenotype in AD lesions in vivo, and its activity is significantly stronger than that of the parent compound.
[0069] 2.2 HW161 exhibits anti-inflammatory and anti-aging activity in primary dermal fibroblasts.
[0070] Given the excellent transmembrane properties of HW161, we isolated primary mouse dermal fibroblasts to evaluate the in vitro safety and efficacy of the compound. CCK-8 assay results showed that the parent compound HW001 began to inhibit fibroblast proliferation at ≥ 500 µM, with a safe upper limit of concentration of approximately 500 µM; while HW161 showed no significant decrease in cell viability even at concentrations as high as 2 mM, exhibiting a safety window approximately four times wider than that of the parent compound. Figure 11 A). This result confirms that structural simplification not only significantly improves transdermal efficiency but also enhances the compound's cellular compatibility, providing strong support for the safety of subsequent long-term in vivo administration.
[0071] To simulate the inflammatory senescence phenotype of fibroblasts in the AD microenvironment, we established an in vitro inflammatory senescence model by stimulating primary fibroblasts with a combination of IL-4 and IL-6, and intervened with equimolar amounts of HW001 or HW161. SA-β-gal staining quantification showed that the proportion of SA-β-gal-positive cells significantly increased after IL-4 / IL-6 treatment, while HW161 intervention significantly reversed this senescence phenotype, with better results than the same concentration of HW001. Figure 11 B). Western blot analysis further showed that IL-4 / IL-6 stimulation upregulated the expression levels of BAX and BAK1, key effector proteins of MOMP, while HW161 treatment dose-dependently downregulated BAX and BAK1. Figure 11 C), compared with in vivo immunohistochemical results ( Figure 10 D) Consistent direction. Based on the above in vitro and in vivo data, HW161, compared with its parent compound HW001, retains the core anti-AD activity while also exhibiting higher cellular safety, better transdermal efficiency, and stronger MOMP pathway regulation ability, providing sufficient basis for target identification and drug development studies.
[0072] Example 4: Target Identification and Mechanism Verification
[0073] Click chemistry-based chemical proteomics and multiple biophysical verification identified PKM2 as a direct target of HW161.
[0074] 1. Experimental Methods
[0075] 1.1 Click chemistry combined with protein proteomics target fishing
[0076] Click chemistry is a highly efficient and selective chemical reaction method that can specifically label and capture target proteins. HW161, a compound with an acetylene group, can specifically bind to target proteins modified with aptamers (such as probes with amino or other functional groups) using click chemistry. The technical route is as follows: Figure 12 As shown.
[0077] (1) Design and optimization of click chemical reactions: 1) Reaction Mechanism: The click chemistry reaction employs a "copper-catalyzed coupling reaction between azido and acetylene groups," a highly selective, rapid, and side-effect-free chemical reaction. The acetylene group in HW161 reacts with a specific azido-labeled probe to form a stable covalent bond, thus labeling the target protein.
[0078] 2) Click to optimize chemical reaction conditions: Select suitable copper catalysts and reaction solvents, and control reaction time and temperature to improve reaction efficiency and specificity. While ensuring reaction selectivity, avoid damage to the target protein.
[0079] (2) Protein sample preparation: 1) Extraction of target proteins: Proteins were extracted from an in vitro cell model of Alzheimer's disease (HaCaT cells) and protein extraction buffer and protease inhibitors were used to ensure protein stability.
[0080] 2) Labeling target proteins: HW161 was mixed with an azide-containing chemical probe, and HW161 was labeled onto the target protein via a click chemistry reaction catalyzed by copper. Subsequently, the target protein was enriched using immunoprecipitation or affinity chromatography.
[0081] (3) Protein proteomic analysis and fishing target: 1) Protein precipitation and purification: HW161-labeled proteins are enriched using antibody or affinity chromatography methods, impurity proteins are removed, and the target protein is purified. This process can be optimized using centrifugation and chromatographic techniques (such as affinity chromatography, gel permeation chromatography, etc.).
[0082] 2) Protein proteometry (MS) analysis: Enriched protein samples were analyzed using liquid chromatography-tandem mass spectrometry (LC-MS / MS). Target proteins binding to HW161 were identified and quantified by comparing the mass spectra of HW161-labeled proteins and control proteins. The identity and functional information of the proteins were confirmed by comparing them with a database.
[0083] 3) Data processing and analysis: Mass spectrometry data were analyzed using the data mining software Proteome Discoverer to identify target proteins that interact with HW161.
[0084] 1.2 Cell thermal transfer assay (CESTA) to verify the binding of small molecules to target proteins.
[0085] CESTA is a chemical enrichment and selective targeting method used to screen compounds for binding to their target proteins and further confirm the targets. In this study, CESTA technology was used to verify the interaction between HW161 and its target protein PKM2.
[0086] (1) CESTA Experimental Design: 1) HW161 Labeling: First, HW161 is bound to an azide-labeled probe via a click chemistry reaction. The probe then forms a stable chemical bond with the acetylene group on HW161 via a copper-catalyzed reaction. In this way, HW161 is successfully labeled for the identification and capture of target proteins in experiments.
[0087] 2) Protein extraction and enrichment: Proteins were extracted from AD animal models or in vitro keratinocytes and enriched using HW161-labeled probes. The complexes of HW161 bound to its target proteins were separated from the complex protein mixture by affinity chromatography or immunoprecipitation.
[0088] 3) Purification of enriched proteins: The enriched target proteins were confirmed by SDS-PAGE electrophoresis and WB analysis to identify the HW161-labeled protein complex, and the target proteins were further identified by MS analysis.
[0089] (2) CESTA Experimental Analysis: 1) Protein identification: Mass spectrometry (MS) was used to analyze the enriched target proteins to confirm the binding of HW161 to PKM2 and other potential target proteins. Through data comparison, proteins binding to HW161 were identified and their functions were analyzed.
[0090] 2) Analysis and verification: By comparing the enrichment of proteins at different time points and under different drug treatments (HW161, dexamethasone, and untreated group), the binding strength of HW161 to PKM2 and its effect on the target protein were further verified, and the mechanism of HW161's preventive effect on AD was explored.
[0091] 1.3 Surface plasmon resonance (SPR) experiment to verify the binding characteristics of small molecules to target proteins
[0092] Surface plasmon resonance (SPR) is a technique based on the principle of surface plasmon resonance used to detect interactions between molecules in real time, and is particularly suitable for analyzing the binding kinetics of small molecule compounds and their target proteins. In this study, SPR will be used to quantitatively analyze the binding characteristics of HW161 and PKM2, including parameters such as binding rate, dissociation rate, and affinity.
[0093] (1) Immobilization of target proteins: Target proteins such as PKM2 are immobilized onto the surface of an SPR sensor chip via chemical coupling. Common immobilization methods include reacting the amino group of an amino-modified chip with the amino group of an amino acid residue (such as lysine), or immobilizing the target protein using the biotin-avidin system.
[0094] (2) Preparation of HW161 solution: Prepare HW161 solutions of different concentrations and inject them into the SPR sensor via microinjection to detect the binding of HW161 to the target protein in real time.
[0095] (3) Experimental setup and data acquisition: In the experiment, HW161 solution at different concentrations flowed through the surface of a sensor chip immobilized with the target protein. The SPR device monitored changes in surface plasmon resonance, which were directly related to the degree of intermolecular binding. By recording the response signal, binding kinetic data (such as binding constant and affinity) between HW161 and PKM2 could be obtained.
[0096] 1.4 Molecular docking analysis of the binding sites and interaction modes of HW161 and PKM2
[0097] Molecular docking simulations can be used to predict the binding sites and interaction modes of HW161 and PKM2, and to further explore the regulatory role of HW161 in PKM2 activity. This study not only helps to elucidate the mechanism of action of HW161, but also provides important evidence for subsequent optimization of HW161's targeting and efficacy.
[0098] (1) Molecular docking simulation
[0099] 1) Protein Structure Acquisition and Preprocessing: The three-dimensional structure of PKM2 was obtained from the Protein Database (PDB). Complete PKM2 proteins (if available with active site and domain information) were preprocessed to remove water molecules and redundant chains, retaining important active sites. The protein structure was optimized using molecular simulation software (such as AutoDock, Dock, GOLD, etc.) to ensure suitability for molecular docking analysis.
[0100] 2) Construction and optimization of HW161 molecule: The three-dimensional structure of HW161 was constructed using software such as ChemDraw, its geometry was optimized, unreasonable structures were removed, and the molecule was ensured to meet the requirements of molecular docking. Based on the chemical structure of HW161 (containing acetylene groups), its active structural domains were predicted.
[0101] 3) Molecular docking simulation: AutoDock was used to simulate the docking of HW161 and PKM2. First, the active or potential binding sites of PKM2 were selected. Then, the HW161 molecule was docked with the active site of PKM2, and the binding energy and binding mode were calculated. By optimizing the docking results, the conformation with the strongest binding affinity was selected.
[0102] (2) Combined with pattern analysis
[0103] 1) Binding Site Prediction: After molecular docking, the binding sites and spatial arrangement of HW161 and PKM2 are analyzed. The docking results clarify the binding site of HW161 on PKM2 and whether this site involves the active site or key regulatory regions of PKM2. Based on the characteristics of the binding sites, the potential impact of HW161 on PKM2 function is predicted.
[0104] 2) Interaction Mode Analysis: Based on the molecular docking results, the interaction modes between HW161 and PKM2 were analyzed in detail, including hydrogen bonding, hydrophobic interactions, van der Waals forces, and electrostatic forces. On this basis, the binding stability and affinity between HW161 and PKM2 were evaluated.
[0105] 3) Binding energy assessment: The binding energy and free energy change (ΔG) of molecular docking were calculated to assess the affinity of HW161 for PKM2. A lower binding energy (i.e., a negative value) indicates a stronger binding affinity, further verifying whether the interaction between HW161 and PKM2 has physiological significance.
[0106] (3) PKM2 activity assessment
[0107] PKM2 activity assay (WB or ELISA) was used to assess the inhibitory or activating effects of HW161 on PKM2 and its influence on PKM2 phosphorylation levels.
[0108] 2. Results
[0109] 2.1. Target Discovery: HaCaT cell lysates were co-incubated with HW161 at concentration gradients (25 / 50 / 100 / 200 µM). Azide-Cy3 (labeled for verification) and biotin-azide (enriched by streptavidin magnetic beads) probes were linked via a copper-catalyzed azido-alkynyl cycloaddition (CuAAC) reaction using terminal alkyne bonds. LC-MS / MS proteomics analysis was then performed. The HW161 group specifically enriched 196 proteins, 71 of which showed significantly higher signal intensities than the DMSO control group. GO / KEGG enrichment analysis revealed that candidate proteins were significantly enriched in energy metabolism pathways such as glycolysis / gluconeogenesis, pyruvate metabolism, and the TCA cycle. The direct target was identified as PKM2 (pyruvate kinase M type, with a peptide coverage of 48.1%, ranking first among candidate proteins in the glycolysis pathway).
[0110] 2.2. Validation: (i) Cellular thermal shift analysis (CETSA) showed that HW161 significantly increased the soluble proportion of PKM protein at a gradient temperature of 52-72 °C, and the thermal stability curve shifted significantly to the right; (ii) Drug affinity target stability (DARTS) showed that the hydrolytic resistance of PKM to pronase increased in a dose-dependent manner with increasing HW161 concentration (0.1→2 mM), while β-actin was unaffected; (iii) Surface plasmon resonance (SPR) determined that the equilibrium dissociation constant KD of HW161 and recombinant PKM2 was 1.903 μM, confirming that the two have a direct binding with moderate affinity. (iv) Molecular docking showed that HW161 anchored to the surface pocket of PKM2 and formed key hydrogen bonds with Arg-399 residues through the side chain guanidine group and carbonyl oxygen with bond lengths of 2.6 Å and 2.7 Å.
[0111] 2.3. Functional validation: At both the cellular and animal levels, HW161 significantly downregulated the expression of MOMP key proteins BAX and BAK1 and the aging marker p21.
[0112] To elucidate the molecular mechanism by which HW161 regulates the MOMP pathway, we utilized the pre-defined terminal alkyne bond on the derivative molecule as a "click chemistry" modification site to conduct an activity-based chemical proteomics target identification study. We first verified the reactivity accessibility of the terminal alkyne group of HW161 in a complex proteomic context. HaCaT cell lysates were co-incubated with different concentrations (25, 50, 100, 200 µM) of HW161, followed by a copper-catalyzed azido-alkynyl cycloaddition (CuAAC) reaction to ligate an azide-Cy3 fluorescent probe. Fluorescence imaging after SDS-PAGE showed that the Cy3 signal intensity increased in a dose-dependent manner with increasing HW161 concentration, while the DMSO control group showed no significant signal. Coomassie brilliant blue staining below showed uniform protein loading across all groups. Figure 13A). This result confirms that the terminal alkyne group on HW161 can be effectively captured by azide probes under physiological conditions, and can serve as a chemical anchor for subsequent protein target fishing.
[0113] Streptavidin enrichment and LC-MS / MS identification: HaCaT cell lysates were incubated with gradient concentrations of HW161, followed by CuAAC reaction and ligation with a biotin-azide probe. Streptavidin magnetic beads were then used to enrich the HW161 covalently bound protein complex. Coomassie brilliant blue staining showed that the HW161-treated group exhibited multiple distinct enrichment bands in the 10–250 kDa range, with the enrichment intensity increasing with increasing HW161 concentration. In contrast, the DMSO control group showed extremely low background signal, confirming the good specificity of the magnetic bead enrichment step. Figure 13 B). The enriched proteins were digested with trypsin and then analyzed by LC-MS / MS. The chromatograms of the HW161 (200 µM) group and the DMSO control group showed significant differences. Figure 13 C).
[0114] Bioinformatics enrichment analysis identified PKM2 as the primary candidate target: GO (BP / MF) and KEGG enrichment analyses were performed on all identified proteins. The results showed that HW161-binding proteins were significantly enriched in core energy metabolism pathways such as glycolysis / gluconeogenesis, pyruvate metabolism, the TCA cycle, and ATP metabolism, and also involved in peroxidase activity and redox-related functions. Figure 13 D). Wien analysis further showed that 196 proteins were detected in both the HW161 group and the DMSO control group, of which 71 proteins showed significantly higher signal intensity in the HW161 group than in the control group; in the list of top candidate target proteins ranked by abundance, pyruvate kinase M (PKM) ranked first among glycolysis pathway-related proteins with a sequence coverage of 48.1%, far exceeding other candidate proteins such as RACK1 (13.2%) and CA2 (11.2%). Figure 13 E). Representative secondary mass spectra of PKM characteristic peptides (good b / y ion matching, containing characteristic peptides such as TGQMLHGLGR) further confirmed the reliability of the protein identification. Figure 13 F). Given the central role of PKM2 in the regulation of keratinocyte metabolism-inflammation-mitochondrial homeostasis, we identified it as the primary candidate direct target for further validation.
[0115] To confirm that PKM2 is the direct binding target of HW161, multiple biological and physical methods were used to verify the direct binding of HW161 to PKM2. CETSA results showed that HaCaT cell lysates, after pre-incubation with HW161 or DMSO, were heated at 52, 57, 62, 67, and 72 °C. Western blot results showed that PKM protein gradually denatured and precipitated with increasing temperature, but the HW161-treated group retained more soluble PKM than the DMSO group at all temperature points, and the thermostability curve shifted significantly to the right. The β-Actin internal control band was consistent between the two groups, confirming that HW161 binding significantly improves the thermodynamic stability of PKM. Figure 13 G). DARTS results showed that, under constant pronase concentration (1:300), the resistance of PKM protein to protease hydrolysis increased in a dose-dependent manner with increasing HW161 concentration (0.1→2 mM), while β-Actin was unaffected, indicating that HW161 specifically binds to PKM and protects it from protease hydrolysis. Figure 13 H). In the SPR experiment, recombinant PKM2 protein was immobilized on a CM5 chip, and HW161 was flowed through the chip surface at a gradient concentration. The binding-dissociation curve was fitted with a steady-state affinity model, and the equilibrium dissociation constant K~D~=1.903 µM was obtained, confirming that there is a direct interaction of moderate affinity between the two in a cell-free system. Figure 13 I, left). Molecular docking reveals the precise binding site of HW161 and PKM2: To further determine the binding interface, we performed molecular docking simulations using the PKM2 crystal structure as a template. The results predict that HW161 can be anchored within a surface pocket of PKM2, with its glycerol ester backbone forming a stable interaction network with multiple amino acid residues. Among them, Arg-399 forms a key hydrogen bond (bond lengths 2.6 Å and 2.7 Å) with the carbonyl oxygen of HW161 through a side-chain guanidinium group. Figure 13 (I, Middle). Arg-399 is located near the known allosteric regulatory pocket of PKM2, suggesting that HW161 may regulate the enzymatic activity or allosteric state of PKM2 by binding to this site.
[0116] The above are merely preferred embodiments of the present invention. It should be noted that those skilled in the art can make various improvements and modifications without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.
Claims
1. A triglyceride compound, characterized in that, It has the structure shown in formula (I) or a pharmaceutically acceptable salt thereof, a solvent compound of said pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereomer, a tautomer, a racemate or a combination thereof; Equation (I); Among them, R1, R2, and R3 are each independently -(CH2). n -C≡CH, where n is an integer from 3 to 8.
2. The triglyceride compound according to claim 1, characterized in that, The structures of R1, R2 and R3 are the same.
3. The triglyceride compound according to claim 1 or 2, characterized in that, It has the structure of formula (II): Formula (II).
4. A method for preparing the triglyceride compound according to any one of claims 1 to 3, characterized in that, Includes the following steps: Step 1: Mix ω-alkynyl acid with thionyl chloride and obtain ω-alkynyl chloride through an acyl chloride reaction; Step 2: Mix the ω-acetyl chloride from Step 1 with glycerol, and obtain the triglyceride compound through an esterification reaction; The structural formula of the ω-alkynetic acid is HOOC-(CH2). n -C≡CH, where n is an integer from 3 to 8.
5. The preparation method according to claim 4, characterized in that, The ω-alkynical acid is hept-6-alkynical acid, and the reagents for the esterification reaction also include triethylamine; The molar ratio of ω-alkynyl acid, thionyl chloride, glycerol and triethylamine is 7.93:11.9:2.50:10.
0.
6. The use of the triglyceride compound according to any one of claims 1 to 3 or the triglyceride compound prepared by the preparation method according to claim 4 or 5 in the preparation of medicaments for the prevention and / or treatment of inflammatory skin diseases.
7. The application according to claim 6, characterized in that, The inflammatory skin diseases include at least one of contact dermatitis, atopic dermatitis, eczema, actinic keratosis, keratinization disorder, bullous epidermolysis, pemphigus, exfoliative dermatitis, seborrheic dermatitis, erythema, damage caused by the sun or other light sources, discoid lupus erythematosus, dermatomyositis, and psoriasis.
8. The use of the triglyceride compound according to any one of claims 1 to 3 or the triglyceride compound prepared by the preparation method according to claim 4 or 5 in the preparation of a drug for inhibiting inflammatory aging of skin cells and / or regulating mitochondrial MOMP function.
9. The use of the triglyceride compound according to any one of claims 1 to 3 or the triglyceride compound prepared by the preparation method according to claim 4 or 5 in the preparation of a drug targeting PKM2 protein.
10. The application according to any one of claims 6 to 9, characterized in that, The drug dosage form is any one of ointment, cream, gel, external solution, paste, plaster, rubber plaster, plaster, tincture, lotion, coating, powder, and lyophilized powder.
11. A drug, characterized in that, It includes triglyceride compounds as described in any one of claims 1 to 3 or triglyceride compounds prepared by the preparation method described in claim 4 or 5, as well as pharmaceutically acceptable excipients.
